Zoetis Showcases Robust R&D Pipeline and Expansion Into New Animal Health Markets

Reuters

Dec 02, 2025

Zoetis Showcases Robust R&D Pipeline and Expansion Into New Animal Health Markets

Zoetis Inc., the world's leading animal health company, announced updates on its scientific research and development during an Innovation Webcast. The company highlighted its robust and diversified R&D pipeline, which targets significant unmet medical needs in animal health. Zoetis is expanding into new therapeutic areas, including chronic kidney disease, oncology, and cardiology, representing over $5 billion in total addressable market opportunity. The webcast emphasized Zoetis' integrated science-to-scale model, leveraging scientific and veterinary expertise to efficiently transform discoveries into approved products. These updates were presented during the webcast and underscore Zoetis' commitment to driving innovation and long-term growth in animal health.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zoetis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251201258345) on December 02, 2025, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2588058934"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2588058934\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2588058934?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-02 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588058934","market":"fut","top_or_hot":-1,"title":"Zoetis Showcases Robust R&D Pipeline and Expansion Into New Animal Health Markets","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zoetis Showcases Robust R&amp;D Pipeline and Expansion Into New Animal Health Markets\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ZTS\">Zoetis Inc.</a>, the world's leading animal health company, announced updates on its scientific research and development during an Innovation Webcast. The company highlighted its robust and diversified R&amp;D pipeline, which targets significant unmet medical needs in animal health. Zoetis is expanding into new therapeutic areas, including chronic kidney disease, oncology, and cardiology, representing over $5 billion in total addressable market opportunity. The webcast emphasized Zoetis' integrated science-to-scale model, leveraging scientific and veterinary expertise to efficiently transform discoveries into approved products. These updates were presented during the webcast and underscore Zoetis' commitment to driving innovation and long-term growth in animal health.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zoetis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251201258345) on December 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zoetis Showcases Robust R&D Pipeline and Expansion Into New Animal Health Markets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZoetis Showcases Robust R&D Pipeline and Expansion Into New Animal Health Markets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-02 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zoetis Showcases Robust R&amp;D Pipeline and Expansion Into New Animal Health Markets\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ZTS\">Zoetis Inc.</a>, the world's leading animal health company, announced updates on its scientific research and development during an Innovation Webcast. The company highlighted its robust and diversified R&amp;D pipeline, which targets significant unmet medical needs in animal health. Zoetis is expanding into new therapeutic areas, including chronic kidney disease, oncology, and cardiology, representing over $5 billion in total addressable market opportunity. The webcast emphasized Zoetis' integrated science-to-scale model, leveraging scientific and veterinary expertise to efficiently transform discoveries into approved products. These updates were presented during the webcast and underscore Zoetis' commitment to driving innovation and long-term growth in animal health.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zoetis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251201258345) on December 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZTS","symbol_name":"Zoetis Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL3bwR4z:1","article_id":"2588058934","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588058934","pubTimestamp":1764678627,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Zoetis Inc., the world's leading animal health company, announced updates on its scientific research and development during an Innovation Webcast. The company highlighted its robust and diversified R&D pipeline, which targets significant unmet medical needs in animal health. Zoetis is expanding into new therapeutic areas, including chronic kidney disease, oncology, and cardiology, representing over $5 billion in total addressable market opportunity. The webcast emphasized Zoetis' integrated science-to-scale model, leveraging scientific and veterinary expertise to efficiently transform discoveries into approved products. These updates were presented during the webcast and underscore Zoetis' commitment to driving innovation and long-term growth in animal health.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ZTS":"Zoetis Inc.","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2308191902.HKD":"BNP PARIBAS ECOSYSTEM RESTORATION \"CLASSIC\" (HKD) ACC","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","BK4588":"碎股","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU0345774631.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) INC","BK4007":"制药","LU0079474960.USD":"联博美国增长基金A","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","LU0345774391.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) ACC","LU0107464264.USD":"abrdn SICAV I - GLOBAL INNOVATION EQUITY \"A\" (USD) ACC","LU1721429402.USD":"BNP PARIBAS SMART FOOD \"C\" (USD) ACC","LU0385154629.USD":"贝莱德营养科学基金A2","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU1721429741.USD":"BNP PARIBAS SMART FOOD \"CRH\" (USD) INC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","IE00B19Z9505.USD":"美盛-美国大盘成长股A Acc","LU0058720904.USD":"联博国际健康护理基金A","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC"},"translate_title":"硕腾展示强大的研发渠道和向新动物保健市场的扩张","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZTS":0.9},"content_text":"Zoetis Showcases Robust R&D Pipeline and Expansion Into New Animal Health Markets\n    \n\nZoetis Inc., the world's leading animal health company, announced updates on its scientific research and development during an Innovation Webcast. The company highlighted its robust and diversified R&D pipeline, which targets significant unmet medical needs in animal health. Zoetis is expanding into new therapeutic areas, including chronic kidney disease, oncology, and cardiology, representing over $5 billion in total addressable market opportunity. The webcast emphasized Zoetis' integrated science-to-scale model, leveraging scientific and veterinary expertise to efficiently transform discoveries into approved products. These updates were presented during the webcast and underscore Zoetis' commitment to driving innovation and long-term growth in animal health.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zoetis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251201258345) on December 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}